Early phase development of inhaled antibiotics to treat serious, hospital-acquired respiratory infections with highly antibiotic-resistant organisms. By combining novel formulations of proven antibiotics with cutting edge drug delivery technology, Cardeas is addressing significant unmet medical needs in the critical-care setting.
Member count: 11-50
Total raised: $34M
Founded date: 2010
Investors 1
| Date | Name | Website |
| - | Delphi Ven... | delphivent... |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 22.05.2013 | Series B | $34M | - | geekwire.c... |
Mentions in press and media 3
| Date | Title | Description | Category | Author | Source |
| 23.12.2013 | Deals of t... | Venture capital investing in W... | - | John Cook | geekwire.c... |
| 23.05.2013 | Cardeas Ph... | Cardeas Pharma Corporation, a ... | funding S... | - | finsmes.co... |
| 22.05.2013 | Bruce Mont... | Bruce Montgomery It has been ... | - | John Cook | geekwire.c... |